Enclomiphene and IGF-1 move in opposite directions. Enclomiphene is an oral testosterone therapy option that raises testosterone by stimulating your own production. It works for secondary hypogonadism but consistently lowers IGF-1, a liver-produced growth factor the body uses for muscle repair. That shift is addressable once you know what to expect.
How enclomiphene affects key hormone markers
| Marker | Typical direction | Why it matters |
|---|---|---|
| LH and FSH | Increases | Signals the testes to produce natural testosterone |
| Testosterone | Increases | Supports energy, libido, and body composition |
| IGF-1 | Often decreases | Can slow muscle repair if not addressed |
| Estrogen activity in the liver | Modulated | The underlying mechanism for the IGF-1 drop |
Does enclomiphene lower IGF-1 levels?
Yes. The drop is real and measurable. Enclomiphene modulates estrogen-related pathways in liver tissue. Estrogen activity in the liver supports IGF-1 synthesis, so when enclomiphene adjusts those signals, IGF-1 output falls.
A 2013 pharmacodynamic study by Wiehle et al. in BJU International documented that enclomiphene testosterone levels rose substantially in men treated for secondary hypogonadism. When researchers compared results against topical testosterone, the IGF-1 reduction was more pronounced with enclomiphene even as testosterone climbed. A 2025 systematic review and meta-analysis by Hohl et al. in Archives of Endocrinology and Metabolism confirmed that enclomiphene raises testosterone in men with hypogonadism, while downstream marker responses varied across study participants.
A licensed provider determines the dose after labs and monitors changes at follow-up.
What happens to IGF-1 when testosterone rises?
Not what you might expect. Higher testosterone and higher IGF-1 do not automatically move together. With enclomiphene, testosterone and IGF-1 levels can clearly diverge: testosterone climbs while IGF-1 falls. This matters for body composition goals because both markers drive recovery through distinct pathways.
How does enclomiphene affect growth hormone?
Enclomiphene does not suppress growth hormone directly. The connection runs through the IGF-1 and growth hormone axis. Growth hormone released by the pituitary travels to the liver and prompts IGF-1 production, which then circulates to support muscle repair, cellular maintenance, and recovery throughout the body.
A 2023 review by García-Arnés et al. in Revista Clínica Española described IGF-1 as the primary clinical proxy for growth hormone activity, because it reflects downstream liver output of the GH signal. Enclomiphene alters the estrogen signals in the liver that normally amplify that output. Growth hormone from the pituitary may hold steady while liver conversion of the signal into IGF-1 falls. The deficit is at the conversion step, not the source.
Can you take sermorelin with enclomiphene?
Yes. Sermorelin stimulates the pituitary to release natural growth hormone in pulses that match your body's own rhythm, sending the signal for the liver to produce more IGF-1 through its normal pathway. The sermorelin IGF-1 increase directly addresses the gap that enclomiphene creates at the liver conversion step.
A 2016 abstract by Helo et al. in the Journal of Urology examined serum levels in men receiving both enclomiphene and a growth hormone-releasing peptide, providing early clinical data on this combination.
A 2020 analysis by Sinha et al. in Translational Andrology and Urology found that growth hormone secretagogues raise IGF-1 and support body composition in hypogonadal men. Pairing sermorelin with enclomiphene keeps natural testosterone production active while restoring IGF-1 to a functional range. For guidance on when to add peptides to a hormone protocol, including timing and monitoring, the peptide cycling guide covers the key points.
Does enclomiphene affect muscle recovery?
Yes, indirectly. The connection between enclomiphene and IGF-1 is what drives the recovery effect: IGF-1 contributes to how quickly muscles repair after resistance training, how the body handles training stress, and overall tissue maintenance. A noticeable drop in IGF-1 during enclomiphene therapy may result in modestly slower recovery between sessions or reduced adaptation over time if left unaddressed.
Studies note this dynamic in men on enclomiphene. Sinha et al. highlighted in their 2020 review that restoring IGF-1 through growth hormone secretagogues improves recovery-related outcomes in hypogonadal men. The practical effect depends on your starting point: men with higher baseline IGF-1 often notice little change, while those with lower baselines or high training volume are more likely to feel the difference.
Monitoring enclomiphene and IGF-1 levels over time
Get baseline bloodwork before you start. Your panel should include testosterone, LH, FSH, and IGF-1 at minimum. This gives your provider a clear reference before any intervention begins.
The Endocrine Society's 2018 clinical practice guideline by Bhasin et al. recommends systematic monitoring of testosterone and related markers in men receiving treatment for hypogonadism. That principle extends to tracking IGF-1 alongside enclomiphene testosterone levels on a combined protocol.
Follow-up labs every few months let your provider track how markers shift and adjust the approach. For a complete guide to what your panel should include, see your hormone panel before starting therapy.
A 2016 review by Rodriguez et al. in Expert Opinion on Pharmacotherapy described enclomiphene citrate as a targeted approach to secondary hypogonadism treatment that preserves the natural production pathway, an advantage when fertility matters.
Providers at Vita Bella offer enclomiphene alongside sermorelin and build protocols around your labs and goals.
Enclomiphene and IGF-1: take the next step
A licensed provider determines the dose after labs and monitors your testosterone and IGF-1 levels over time. Whether you need enclomiphene alone or a combination approach with sermorelin, the right protocol starts with a complete lab review.
Frequently asked questions
Not equally. IGF-1 reductions vary based on baseline levels, how each body responds to estrogen modulation in the liver, and individual physiology. Some men experience minimal change, while others see a more significant drop, which is why regular bloodwork matters.
Yes. Sermorelin stimulates natural growth hormone release, which then signals the liver to produce more IGF-1. Research on growth hormone secretagogues in hypogonadal men confirms this approach raises IGF-1 and supports body composition outcomes.
Common enclomiphene side effects men may notice include mood changes, visual disturbances, and shifts in estrogen levels. The IGF-1 reduction is a less-discussed but clinically measurable effect. Routine bloodwork helps your provider identify and address any changes early.
Enclomiphene raises LH and FSH to stimulate your own testosterone production rather than supplying testosterone directly. This keeps the natural production pathway active and preserves fertility. Testosterone and IGF-1 levels respond differently with enclomiphene compared to direct replacement therapy.
Yes. Baseline testosterone, LH, FSH, and IGF-1 measurements give your provider a starting point and inform the right protocol. Follow-up labs track how your markers change during treatment.
Sources
- Wiehle RD et al. (2013). Testosterone restoration using enclomiphene citrate in men with secondary hypogonadism: a pharmacodynamic and pharmacokinetic study. BJU International.
- Helo S et al. (2016). Serum levels of enclomiphene and growth hormone releasing peptide treatment in men. Journal of Urology. (Abstract)
- Sinha DK et al. (2020). Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Translational Andrology and Urology.
- Hohl A et al. (2025). Clomiphene or enclomiphene citrate for the treatment of male hypogonadism: a systematic review and meta-analysis of randomized controlled trials. Archives of Endocrinology and Metabolism. PubMed
- García-Arnés JA et al. (2023). Doping and sports endocrinology: growth hormone, IGF-1, insulin, and erythropoietin. Revista Clínica Española. PubMed
- Rodriguez KM et al. (2016). Enclomiphene citrate for the treatment of secondary male hypogonadism. Expert Opinion on Pharmacotherapy. PubMed
- Bhasin S et al. (2018). Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology and Metabolism. PubMed
